Assyro AI

FDA Orange Book · active-ingredient family

Mycophenolate mofetil hydrochloride

Mycophenolate mofetil hydrochloride is approved as 1 brand and 8 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:CELLCEPT · NDA 050758

1

Brand (NDA)

8

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
CELLCEPTRLDROCHE PALONDA 050758APAug 12, 1998

Generic (ANDA) products (8)

ProductApplicantApplicationTEApproved
MYCOPHENOLATE MOFETIL HYDROCHLORIDEBPI LABSANDA 214283APJun 01, 2023
MYCOPHENOLATE MOFETIL HYDROCHLORIDEONESOURCE SPECIALTYANDA 216390APDec 23, 2022
MYCOPHENOLATE MOFETIL HYDROCHLORIDEAMNEALANDA 211374Mar 05, 2021
MYCOPHENOLATE MOFETIL HYDROCHLORIDEMEITHEALANDA 212130APJan 15, 2021
MYCOPHENOLATE MOFETIL HYDROCHLORIDEZYDUS PHARMSANDA 204473APAug 31, 2017
MYCOPHENOLATE MOFETIL HYDROCHLORIDEMYLAN LABS LTDANDA 203859APMar 31, 2017
MYCOPHENOLATE MOFETIL HYDROCHLORIDERISINGANDA 204043APFeb 28, 2017
MYCOPHENOLATE MOFETIL HYDROCHLORIDEPH HEALTHANDA 203575APOct 28, 2016

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Mycophenolate mofetil hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.